Axsome Therapeutics Inc (FRA:19X)
€ 184.25 +0.70 (+0.38%) Market Cap: 9.84 Bil Enterprise Value: 9.75 Bil PE Ratio: 0 PB Ratio: 207.99 GF Score: 30/100

Q2 2026 Axsome Therapeutics Inc Earnings Call Transcript

Aug 10, 2026 / 12:00PM GMT
Release Date Price: €184.25 (+0.38%)
Operator

Good morning, and welcome to the Axsome Therapeutics second quarter 2026 earnings conference call. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions) Please note, this call is being recorded.

I would now like to hand the call over to Ashley Dong, Senior Director of Investor Relations. Please go ahead, Ashley.

Ashley Dong
Axsome Therapeutics, Inc. - Senior Director of Investor Relations

Thank you. Good morning, everyone, and welcome to Axsome's second quarter 2026 Earnings Conference Call. Joining me today to discuss our results for the quarter are Dr. Herriot Tabuteau, Chief Executive Officer; Nick Pizzie, Chief Financial Officer; and Ari Maizel, Chief Commercial Officer, who will begin our call with prepared remarks. Mark Jacobson, our Chief Operating Officer; and Hunter Murdock, our General Counsel, will also be available for Q&A.

Before we begin, I encourage everyone to visit the investors section of our website to find the press release and presentation for today's call. Please note that today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot